Skip to main content

Advertisement

SpringerLink
Log in

Bortezomib

  • Fresh from the Pipeline
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Abstract

On 13 May 2003, Bortezomib (Velcade; Millenium) became the first proteasome inhibitor to be approved by the US FDA. Bortezomib was approved for multiple myeloma, a blood cancer that affects two to three people per 100,000, in record time — four months — on the basis of positive outcomes in early-phase trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Bortezomib and NF-κB.
Figure 2

References

  1. Coux, O., Tanaka, K. & Goldberg, A. L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 65, 801–847 (1996).

    Article  CAS  PubMed  Google Scholar 

  2. King, R. W., Deshaies, R. J., Peters, J. -M. & Kirschner, M. W. How proteolysis drives the cell cycle. Science 274, 1652–1659 (1996).

    Article  CAS  PubMed  Google Scholar 

  3. Kisslev, A. F. & Goldberg, A. L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 121, 1–20 (2001).

    Google Scholar 

  4. Hideshima, T. et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61, 3071–3076 (2001).

    CAS  Google Scholar 

  5. Barnes, P. J. & Karin, M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336, 1066–1071 (1997).

    Article  CAS  Google Scholar 

  6. Palombella, V. J., Rando, O. J., Goldberg, A. L. & Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 78, 773–785 (1994).

    Article  CAS  PubMed  Google Scholar 

  7. Adams, J. Proteasome inhibition in cancer: development of PS-341. Semin. Oncol. 28, 613–619 (2001).

    Article  CAS  Google Scholar 

  8. Adams, J. et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. 8, 333−338 (1998).

  9. Anderson, P. G. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609–2617 (2003).

    Article  Google Scholar 

  10. FDA Drug Approvals List [online] (cited 13 May 2003) <http://www.fda.gov/cder/foi/label/2003/021602lbl.pdf> (2003).

  11. Zangari, M. et al. Marked activity also in Del 13 multiple myeloma (MM) of PS-341 (PS) and subsequent thalidomide (THAL) in a setting of resistance to post-autotransplant salvage therapies. Proc. Am. Soc. Hematol. A387 (2002).

  12. Orlowski, R. Z. et al. Phase I study of the proteasome inhibitor bortezomib (PS-341, ValcadeTM) in combination with pegylated liposomal doxorubicin (DoxilTM) in patients with refractory hematological malignancies. Proc. Am. Soc. Hematol. A388 (2002).

Download references

Author information

Authors and Affiliations

  1. Decision Resources International, 50–51 Russell Square, London, WC1B 4HQ, UK

    Andrew Paramore

  2. Nature Reviews Drug Discovery,

    Simon Frantz

Authors
  1. Andrew Paramore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simon Frantz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew Paramore.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paramore, A., Frantz, S. Bortezomib. Nat Rev Drug Discov 2, 611–612 (2003). https://doi.org/10.1038/nrd1159

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1159

  • Springer Nature Limited

This article is cited by

Search

Navigation